Efficacy and Safety of SKCPT in Patients With Knee Osteoarthritis: Phase III Clinical Trial
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 278
- Registration Number
- NCT05930080
- Locations
- π°π·
Asan Medical Center, Seoul, Korea, Republic of
A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract and Aspirin in Diabetic Peripheral Angiopathy.
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05906199
- Locations
- π°π·
SK chemicals, Seoul, Korea, Republic of
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT05453786
- Locations
- π°π·
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT05445895
- Locations
- π°π·
Asan Medical Center, Seoul, Korea, Republic of
Clinical Trial for GNX80 in Intermittent Claudication
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05400395
- Locations
- π°π·
Korea University Guro Hospital, Seoul, Korea, Republic of
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT05236998
- Locations
- π°π·
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 169
- Registration Number
- NCT04821687
- Locations
- π°π·
Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of
The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04401137
- Locations
- π°π·
Seoul National University Hospital, Dept. of Clinical Pharmacology, Seoul, Korea, Republic of
Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT03893669
- Locations
- π°π·
Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of
Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT03826719
Β© Copyright 2024. All Rights Reserved by MedPath